A BLINDED CONTROLLED STUDY OF ALENDRONATE IN CHRONIC SPINAL CORD INJURY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 众所周知，在脊髓损伤人群中，骨密度会受到影响。这项双盲、安慰剂对照的单中心试验将确定一种名为阿伦磷酸钠的药物是否有能力增加或维持脊髓损伤患者的骨密度，这些患者在受伤后至少18个月。参赛者年龄应在18岁至60岁之间，必须依靠轮椅才能移动。参与者将被要求在一年的时间里每天服用钙和维生素D补充剂，每周服用一次阿伦磷酸钠(或安慰剂)。使用类似X光设备的骨密度测量将在注册时进行，并在6个月和1年后重复进行。实验室测量将在这一年内每三个月进行一次，每次测量都需要访问位于密歇根大学的GCRC实验室。参与者将获得一小笔津贴，以支付他们的旅费和其他参与费用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Bone, Density is known to be compromised in the Spinal Cord Injured Population. This double-blind, placebo-comtrolled, single center trial will ascertain the ability of a medication called alendronate to increase or maintain the bone density of individuals with spinal cord injury who are at least 18 months past their injury. Participants should be between age 18 and 60 and must rely on a wheelchair for mobility. Participants will be asked over a one-year period to take calcium and Vitamin D supplements each day and to take alendronate (or placebo) once each week. Bone density measurements using an x-ray like device will be done at enrollment and repeated at 6 months and one year. Laboratory measurements will be made every three months over that year, and each measurement will require a visit to the GCRC lab at UMMS. Participants will receive a small stipend to cover their travel and other costs of participation.